Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 8 July 2025, researchers at the KEMRI-Wellcome Trust Research Programme began the Phase II trial of the ChAdOx1 RVF vaccine in Kilifi, Kenya—the most advanced Rift Valley fever vaccine study in an outbreak-prone region. Led by Oxford University and funded by CEPI, this milestone brings us closer to a licensed vaccine for protecting lives and livelihoods.

Healthcare worker vaccinating a woman

On July 8, 2025, the clinical trials team at the KEMRI - Wellcome Trust Research Programme began vaccinating volunteers with the ChAdOx1 RVF vaccine candidate in Kilifi, Kenya, as part of a Phase II trial. This is the most advanced stage of testing for vaccines being developed against the potentially deadly disease in an outbreak-affected country – a region where it could be used if this and later stages of testing are successful.

The research study is funded by CEPI and led by University of Oxford, with the promising vaccine candidate using the same technology as the life-saving Oxford-AstraZeneca COVID-19 vaccine.

The launch of the trial is a major vaccine development milestone and takes us closer than ever to having a licensed Rift Valley fever vaccine available for use in people. With Rift Valley fever threatening both people and animals, this work is vital to preventing future outbreaks and protecting both lives and livelihoods. Earlier Phase I studies found the vaccine candidate to be safe and immune-stimulating in volunteers in the UK and Uganda.

CEPI is working to develop vaccines against known threats like Rift Valley fever, and use knowledge and findings to prepare for an unknown ‘Disease X’, in support of the 100 Days Mission. In funding this project, CEPI are boosting regional health security and building systems to more rapidly respond to and prevent new threats. This achievement underscores CEPI’s role as a global health catalyst and demonstrates the impact of continued investment in epidemic preparedness.

 

Read the story on the Centre for Tropical Medicine and Global Health website.

Similar stories

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE).